Background/Aims: Chronic kidney disease (CKD) is a growing public health problem. However, data on risk factors and prevalence of CKD exist only in a small number of countries. Portugal has the highest incidence of end-stage renal disease (ESRD) among European countries, but there are huge disparities among countries. Whether these disparities reflect differences in risk factors, prevalence of CKD or other factors is currently unknown. Methods: We analyzed data from a nationally representative sample of 5,167 subjects, and estimated the prevalence of CKD and associated risk factors, and combined these prevalence estimates with available data on ESRD. Results: The prevalence of risk factors such as diabetes (11.7%), obesity (33.7%), and metabolic syndrome (41.5%) was similar to that in the US, but greater than in most European countries. The prevalence of CKD stages 3–5 was 6.1%, which is similar to that in other Western countries. The risk of ESRD was greater than in other European countries, but lower than in the US. Conclusion: The high incidence of ESRD among the Portuguese population is not due to a greater prevalence of CKD. A higher rate of progression associated with the high prevalence of risk factors may account for the high incidence of ESRD. The role of unmeasured factors needs to be evaluated in further studies.

1.
Schoolwerth AC, Engelgau MM, Hostetter TH, et al: Chronic kidney disease: a public heath problem that needs a public health action plan. Prev Chronic Dis 2006; http://www.cdc.gov/pcd/issues/2006/apr/05_0105.htm.
2.
Zhang Q-L, Rothenbacher D: Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008;8:117–129.
3.
PRTESRD – Portuguese Registry on the Treatment of ESRD. http://www.spnefro.pt/comissoes_gabinetes/Gabinete_registo_2008/default.asp.
4.
DuBose TD: American Society of Nephrology Presidential Address 2006: chronic kidney disease as a public health threat – new strategy for a growing problem. J Am Soc Nephrol 2007;18:1038–1045.
5.
US Renal Data System. USRDS 2007 annual data report: atlas of end-stage renal disease in the United States, National Institutes of Health, Minneapolis. http://www.usrds.org/adr.htm.
6.
Gardete-Correia L, Boavida JM, Raposo JF, Mesquita AC, Fona C, Carvalho R, Massano-Cardoso S: First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med 2010;27:879–881.
7.
IDF Worldwide Definition of the Metabolic Syndrome. http://www.idf.org/metabolic_syndrome.
8.
Lamb EJ, Tomson CRV, Roderick PJ: Estimating kidney function in adults using formulae. Ann Clin Biochem 2005;42:321–345.
9.
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39:S1–S246.
10.
Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
11.
Viktorsdottir O, Palsson R, Andresdottir MB, Aspellund T, Gudnason V, Indridason OS: Prevalence of chronic kidney disease based on estimated glomerular filtration rate and proteinuria in Icelandic adults. Nephrol Dial Transplant 2005;20:1799–1807.
12.
Hallan SI, Coresh JC, Astor BC, et al: International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol 2006;17:2275–2284.
13.
Otero A, Gayoso P, Garcia F, De Francisco AL: Epidemiology of chronic renal disease in the Galician population: results of the pilot Spanish EPIRCE study. Kidney Int Suppl 2005;68:S16–S19.
14.
Jong PE, van der Velde M, Gansevoort RT, Zoccali C: Screening for chronic kidney disease: where does Europe go? Clin J Am Soc Nephrol 2008;3:616–623.
15.
Otero A, de Francisco ALM, Gayoso P, Garcia F: Prevalence of chronic renal disease in Spain: results of the EPIRCE study. Nefrologia 2010;30:78–86.
16.
Coresh J, Selvin E, Stevens LA, et al: Prevalence of chronic kidney disease in the United States. JAMA 2007;298:2038–2047.
17.
Townsend R, Feldman H: Editorial – chronic kidney disease: past problems, current challenges, and future facets. NephSAP 2009;8:239–243.
18.
Educational attainment in the United States: 2003. http://www.census.gov/prod/2004pubs/p20-550.pdf.
19.
Rodríguez-Pose A, Tselios V: Mapping the European regional educational distribution: educational attainment and inequality. http://repec.imdea.org/pdf/imdea-wp2007-18.pdf.
20.
CDC: Prevalence of chronic kidney disease and associated risk factors. JAMA 2007;297:1767–1768.
21.
Iseki K, Ikemiya Y, Kinjo K, Inoue T, Iseki C: Body mass index and the risk of development of end-stage renal disease in a screened cohort. Kidney Int 2004;65:1870–1876.
22.
Hsu C-Y, McCulloch CE, Iribarren C, Darbinian J, Go AS: Body mass index and risk for end-stage renal disease. Ann Intern Med 2006;144:21–28.
23.
Chen J, Muntner P, Hamm L, Jones DW, Batuman V, Fonseca V, Whelton P, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004;140:167–174.
24.
Kurella M, Lo JC, Chertow G: Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005;16:2134–2140.
25.
CDC – MMWR: Racial/ethnic disparities in prevalence, treatment, and control of hypertension – United States, 1999–2002. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5401a3.htm.
26.
Wolf-Maier K, Cooper ES, Banegas JR, et al: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289:2363–2369.
27.
Cowie CC, Rust KF, Byrd-Holt DD, et al: Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006;29:1263–1268.
28.
Stock SA, Redaelli M, Wendland G, et al: Diabetes – prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany. Diabet Med 2006;23:299–305.
29.
World Health Organization: Prevalence of overweight and obesity, 2002. World Health Organization, 2005.
30.
Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the US. Diabetes Care 2005;28:2745–2749.
31.
Buckland GG, Salas-Salvado J, Serra-Majem L, Castell C, Cabré J, Salleras-Sanmartí L: Increase in metabolic syndrome as defined by ATPIII from 1992–1993 to 2002–2003 in a Mediterranean population. Nutr Rev 2009;67:S117–S125.
32.
Hallan SI, Vikse BE: Relationship between chronic kidney disease prevalence and end-stage renal disease risk. Curr Opin Nephrol Hypertens 2008;17:286–291.
33.
Al-Aly Z, Zeringue A, Fu J, et al: Rate of kidney function decline associates with mortality. J Am Soc Nephrol 2010;21:1961–1969.
34.
US Department of Health and Human Services – National Institute of Health: National Diabetes Statistics 2007, NIH publication No. 08-3892, June 2008. www.diabetes.niddk.nih.gov.
35.
Obermayr RP, Temml C, Knechtelsdorfer M, et al: Predictors of new-onset decline in kidney function in a general middle-European population. Nephrol Dial Transplant 2008;23:1265–1273.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.